Sign In
Buy VRTX
$428.34
+3.25 (+0.765%)
At Close: Jun 03, 2026
Vertex (VRTX) Up 0.2% Since Last Earnings Report: Can It Continue?
12:36pm, Wednesday, 03'rd Jun 2026
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?
FDA Accepts Vertex's BLA for Povetacicept in IgA Nephropathy
12:10pm, Tuesday, 02'nd Jun 2026
VRTX moves closer to a potential nephrology launch as the FDA accepts its BLA for povetacicept in adults with IgAN, with a decision due in November 2026.
Got $5,000? 1 Cash-Flow King to Buy and Hold Forever That Wall Street Is Completely Mispricing
12:02pm, Tuesday, 02'nd Jun 2026
Vertex Pharmaceuticals (NASDAQ:VRTX | VRTX Price Prediction) screens as a long-duration compounder because it sits on a global monopoly in cystic fibrosis therapies that generates substantial free cas
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
10:01am, Monday, 01'st Jun 2026
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
08:00am, Monday, 01'st Jun 2026
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) submission
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
01:04pm, Friday, 29'th May 2026
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
These 2 Cheap Biotech Stocks Offer Potential for Low-Beta Growth
11:04am, Thursday, 28'th May 2026
If you're looking to diversify outside of AI, especially as AI investors look to trim their winners to save up for that mega-cap AI IPO boom on the horizon, with SpaceX leading the way, the biotech sp
Vertex Pharmaceuticals Incorporated (VRTX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
04:40pm, Tuesday, 19'th May 2026
Vertex Pharmaceuticals Incorporated (VRTX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Tuesday, 19'th May 2026
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings
02:21pm, Friday, 08'th May 2026
Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
10:01am, Friday, 08'th May 2026
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Vertex Pharmaceuticals Q1 Earnings Review: Pharma May Need Bolder M&A Strategy
12:45pm, Wednesday, 06'th May 2026
Vertex Pharmaceuticals Incorporated delivered strong Q1 2026 earnings, with $2.99bn revenue and $4.02 EPS, but revenue growth is slowing as CF market saturates. VRTX's cystic fibrosis franchise remain
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therap
These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q1 Earnings
02:15pm, Tuesday, 05'th May 2026
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported mixed financial results for the first quarter after the market close on Monday.
CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates
09:21am, Tuesday, 05'th May 2026
CRSP posts a wider Q1 loss and revenues miss, pressuring shares, even as Casgevy sales grow and cash reserves strengthen from recent financing.
